borders books |
||||||
|
News for 19-Jan-25 Source: MedicineNet High Blood Pressure General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General Source: MedicineNet High Blood Pressure General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General
|
The Best borders books websiteAll the borders books information you need to know about is right
here. Presented and researched by http://www.mdnewscast.net. We've searched
the information super highway far and wide to provide you with the
best borders books site on the internet today. The links below will
assist you in your efforts to find the information that you are looking
for about
borders books
Shopping for borders booksWhen you’re shopping for borders books you’ve come to the right place. We’re specialists in this borders books field. You can’t find exactly what you’re looking for on too many other sites, but you can here. Well maybe that’s a slight exaggeration. We might not have got exactly what you’re looking for – borders books – but we know the very best websites to get it from. All you have to do is follow the links below. They’re the very best borders books sites you’re going to find anywhere, and they’re the ones we use ourselves when we want to get information or make a purchase. How do we know they’re the best borders books websites available on the net today? Because we’ve spent months painstakingly researching the subject. We’ve visited every site about borders books we could find, and we’ve studied them to sort the good from the bad. Look, we’re good at getting ranked well in search engines. borders books might be our big interest, but we’ll be the first to admit that out site doesn’t come anywhere near the quality of the websites we’re linking to. So what we suggest you do is follow one the links. You won’t be disappointed. Thanks for visiting our webpage, and please come back again one day. Next time you visit you might find that we’re the best borders books place online. borders books
Our research on many products, including borders books, has revealed that many suppliers are now offering borders books freight free. This will change the numbers in your favour. The only way for you to fully determine the price elements on offer is to click on the links for the borders books merchants which are clearly shown on this page. Our links will take you straight to their website where you will be able to add up the numbers on their online borders books products with those in normal borders books shops. We definitely think the numbers will stack up in your favour. Drug Offers Hope to Cancer Patients by: ARA Content
(ARA) - A decade ago, research into angiogenesis-inhibiting compounds was still in a relative state of infancy. The principle itself was not new -- as far back as the early '70s, there was speculation that human cancer tumors could not grow beyond a few millimeters in diameter without obtaining their own blood supply. But opinion was still divided in the scientific community. Angiogenesis itself is a natural and necessary physiological function, which refers to the process by which new blood vessels form and develop. In its pathological form, however, angiogenesis is also implicated in the progression of more than 20 different diseases, including cancer. In order to grow, solid tumors need to be supplied by blood vessels that act as conduits for oxygen and nutrients. Once a vascular network has been generated around a tumor, cancerous cells can then invade the rest of the body, a process called metastasis. Angiogenesis inhibitors block the formation of new blood vessels, without which cancerous cells are starved and tumors cannot grow. In recent years, the therapeutic potential of angiogenesis inhibitors has gained wide acceptance. Indeed, the scientific community now believes that more than 90 percent of all cancer cases are angiogenesis dependent. The industry spends nearly $4 billion annually in angiogenic research and more than 100 research organizations and companies are currently developing angiogenesis-blocking drugs. Æterna Laboratories Inc. is at the forefront of this effort. In fact, it is one of the very few biotechnology companies in the world with an angiogenesis-blocker in Phase lll clinical development. Its proprietary compound, Neovastat, is currently the subject of Phase III trials in lung and kidney cancer and a Phase ll trial in multiple myeloma, a form of blood cancer. Neovastat possesses multiple mechanisms of action that counteract the angiogenic process. Among competing products, this makes it unique. It has also shown an excellent safety profile in clinical trials. Further advantages of Neovastat are that it is orally administered, which makes it convenient for patients who must receive treatment on a long-term basis, and it may be taken in association with standard therapies such as chemotherapy. Angiogenesis blockers are not a cure for cancer. They are a form of treatment -- in the same way that insulin is a treatment for diabetes -- that should allow patients to lead a more normal life, without suffering from the often debilitating side-effects that some treatments can produce. Æterna's clinical trials strategy has targeted forms of cancer for which there is an urgent need for new therapies. Since 1996, Neovastat has been tested in more than 850 patients in North American and European countries. Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer. For multiple myeloma, the second most common form of blood cancer, the drug is in Phase II trials with 125 patients in the United States, Canada and Europe. This trial should be completed in early 2003. For progressive renal cell carcinoma, the drug is in Phase III trials with 302 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a Phase III trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005. Once the clinical trials are complete, health authorities in various countries can then assess these results and make decisions on approval.
|
|||||
|
http://www.medmeet.com/ |
||||||
| MD News Medical Meetings On The Net Medical Newscast |